Technical Analysis for GBT - Global Blood Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 40.8 | -0.02% | -0.01 |
GBT closed down 0.02 percent on Monday, April 19, 2021, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 4
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical GBT trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
BB Squeeze Started | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -0.02% | |
NR7 | Range Contraction | -0.02% | |
20 DMA Resistance | Bearish | -1.28% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
10 DMA Resistance | about 17 hours ago |
Down 2 % | 4 days ago |
60 Minute Opening Range Breakdown | 4 days ago |
10 DMA Resistance | 4 days ago |
Down 1% | 4 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/04/2021
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hemoglobin Blood Angioedema Hereditary Angioedema Sickle Cell Disease Hemoglobins Pulmonary Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hemoglobin Blood Angioedema Hereditary Angioedema Sickle Cell Disease Hemoglobins Pulmonary Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 83.69 |
52 Week Low | 36.49 |
Average Volume | 877,386 |
200-Day Moving Average | 52.27 |
50-Day Moving Average | 43.81 |
20-Day Moving Average | 41.27 |
10-Day Moving Average | 41.13 |
Average True Range | 1.93 |
ADX | 14.96 |
+DI | 18.60 |
-DI | 22.01 |
Chandelier Exit (Long, 3 ATRs ) | 39.83 |
Chandelier Exit (Short, 3 ATRs ) | 44.11 |
Upper Bollinger Band | 43.70 |
Lower Bollinger Band | 38.85 |
Percent B (%b) | 0.4 |
BandWidth | 11.76 |
MACD Line | -0.73 |
MACD Signal Line | -0.84 |
MACD Histogram | 0.1111 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 41.81 | ||||
Resistance 3 (R3) | 41.82 | 41.49 | 41.64 | ||
Resistance 2 (R2) | 41.49 | 41.24 | 41.49 | 41.58 | |
Resistance 1 (R1) | 41.15 | 41.08 | 41.32 | 41.14 | 41.53 |
Pivot Point | 40.82 | 40.82 | 40.91 | 40.82 | 40.82 |
Support 1 (S1) | 40.48 | 40.57 | 40.65 | 40.47 | 40.07 |
Support 2 (S2) | 40.15 | 40.41 | 40.15 | 40.02 | |
Support 3 (S3) | 39.81 | 40.15 | 39.96 | ||
Support 4 (S4) | 39.80 |